FDA approves BMS’ nivolumab + low-dose ipilimumab for MSI-H/dMMR mCRC progressing after fluoropyrimidine, oxaliplatin, irinotecan

The Food and Drug Administration (FDA) approves Bristol-Myers Squibb’s (BMS’) nivolumab (Opdivo) + low-dose ipilimumab (Yervoy) for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Read more